Heartburn and arthritis drugs tested against COVID-19
NCT ID NCT05077332
First seen Jan 05, 2026 · Last updated Jun 22, 2026 · Updated 26 times
Summary
This Phase 2 trial tested whether combining famotidine (Pepcid) and celecoxib (Celebrex) could help people with COVID-19 recover faster. Only 4 participants were enrolled, making it too small to draw firm conclusions. The study aimed to see if these drugs could reduce symptom severity and prevent hospital visits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID -19 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
US02-04: Integrated Health Solutions
Miami, Florida, 33126, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Famotidine (Pepcid) and celecoxib (Celebrex)
What this could lead to
If it works, this could point toward a safe, over-the-counter drug combination to help manage COVID-19 symptoms at home.
What could go wrong
This was a very small, early-phase trial with only 4 participants, so results are not reliable. The drugs may not work against COVID-19, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.